A Phase IA/IB study evaluating TAS-116 has just been initiated (NCT02965885) involving patients with HER2+ MBC, NSCLC harboring EGFR mutations will be further evaluated for safety, tolerability and efficacy in 3 separate cohorts at recommended dose. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.